Treatment | MNCC (µg/ml) | Antiviral effect on HAV (%) | Antiviral effect on HAV (Qualitative)# | Antiviral Efficiency |
---|
EC50 | CC50 | SI |
---|
Amantadine (control) | 130 | 86.91 ± 5.57 | ++++ | 8.48 ± 0.50 | 325.61 ± 16.9 | 38.39 |
15 N | 60 | 7.24 ± 0.64* | + | 408.14 ± 21.60* | 280.36 ± 19.3* | 0.69 |
- Data is displayed as mean (n = 3) ± standard deviation
- *: represents significant difference (P < 0.05), as compared to the corresponding controls, according to independent t-test. #Where: (+): Weak antiviral activity (1- < 25%), and (++++): Excellent antiviral activity (75–100%)
- Where: ( +): Weak antiviral activity (1– < 25%), and (++++): Excellent antiviral activity (75–100%)